By Siddhi Mahatole July 29 (Reuters) - Medical device maker Boston Scientific cut its annual profit forecast on Wednesday, ...

Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan ...

The medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from ...

Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, citing factors including weak demand for its Watchman heart implant. The medical device maker now ...

The WATCHMAN Left Atrial Appendage Closure Device is more cost-effective than warfarin and non-warfarin oral anticoagulants (NOACs) for stroke reduction in patients with non-valvular atrial ...

Add Yahoo as a preferred source to see more of our stories on Google. Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro ...

Boston Scietific's Watchman left atrial appendage closure (LAAC) device won FDA approval in 2015 after an unprecendented three FDA panel reviews. Since then, the Watchman device has become one of the ...

SAN FRANCISCO, CA—The redesigned Watchman FLX device (Boston Scientific) provides safer left atrial appendage occlusion (LAAO) in patients with atrial fibrillation compared with the first-generation ...

Boston Scientific's Watchman device performed well in the recent quarter, but analysts are focused on upcoming reimbursement decisions for the device and the potential impact on Watchman adoption ...

BOSTON, MA—For patients with atrial fibrillation who are undergoing left atrial appendage occlusion (LAAO), the Amplatzer Amulet (Abbott) and the first-generation Watchman 2.5 (Boston Scientific) ...